I. Medication Description

Aducanumab-avwa is a human monoclonal antibody that selectively binds to amyloid β fibrils and soluble oligomers in the brain. The accelerated FDA approval of this medication was based on a surrogate endpoint, and continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.

II. Position Statement

Aducanumab-avwa is considered experimental/investigational and therefore non-covered as there is a lack of conclusive evidence confirming clinical efficacy.

VII. Billing/Coding Information

- J0172 – aducanumab-avwa, 2 mg

VIII. Summary of Policy Changes

- 07/09/21: new policy
- 1/1/22: updated billing/coding information
- 8/1/22: no policy changes

IX. References


*These guidelines are not applicable to benefits covered under Medicare Advantage. Medicare Advantage benefit coverage requests are reviewed in accordance with the guidance set forth in Chapter 15 Section 50 of the Centers for Medicare & Medicaid Services Medicare Benefit Policy Manual.

The Plan fully expects that only appropriate and medically necessary services will be rendered. The Plan reserves the right to conduct pre-payment and post-payment reviews to assess the medical appropriateness of the above-referenced therapies.

The preceding policy is a guideline to allow for coverage of the pertinent medication/product, and is not meant to serve as a clinical practice guideline.